✦ LIBER ✦

Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population

✍ Scribed by Chen, Ye; Cao, Dan; Bi, Feng; Li, Qiu; Qiu, Meng

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Quality of life analysis in patients wit

✍ Láng, István; Köhne, Claus-Henning; Folprecht, Gunnar; Rougier, Philippe; Curran 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 325 KB

Biweekly cetuximab plus irinotecan as se

✍ Myoung Joo Kang, Yong Sang Hong, Kyu-pyo Kim, Sun Young Kim, Ji Yeon Baek, Min-H 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 166 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

✍ Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Jage 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 225 KB

6078 Cetuximab plus FOLFIRI in 1st-line

✍ Lang, I.; Köhne, C.H.; Folprecht, G.; Nowacki, M.P.; Cascinu, S.; Shchepotin, I. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB